NewAmsterdam Pharma Company NV

Bull case

NewAmsterdam Pharma Co is viewed favorably because obicetrapib has repeatedly shown meaningful LDL reductions in multiple ph.I and ph.II studies, with 40% LDL lowering cited as potentially translating into a 20% lower MACE risk. The company’s 9,500-patient outcomes trial is more than 90% powered to show a 20% risk reduction, while the final analysis is seen as having a nearly 98% PoS on MACE-4 at p=0.05, supported by an additional year of event accrual. Investor confidence is further reinforced by a clean safety profile, favorable oral once-daily dosing, and a large unmet need in which as many as 50% of U.S. patients miss cholesterol goals and the drug could support more than $3.1B in worldwide end-user sales.

Bear case

• NewAmsterdam Pharma Co is viewed negatively because its value depends heavily on obicetrapib proving that LDL-C reductions translate into meaningful MACE benefit, yet the cited HORIZON readout for pelacarsen showed that lowering Lp(a) did not reduce MACE, increasing skepticism toward the broader cardiovascular-risk-reduction thesis.
• The company also faces class-level and execution risks: prior CETP inhibitors have failed, commercialization may be difficult in a highly genericized market with other branded options, and the composition-of-matter patent expires in 2027, leaving weaker IP to defend exclusivity.
• As a small, non-revenue-generating biotech, NewAmsterdam Pharma Co must still finance ongoing R&D while managing safety, regulatory, manufacturing, reimbursement, and trial risks, and the text explicitly warns that failure to convert LDL lowering into MACE benefit could leave shares trading at cash, about $4/sh.